Malignant Gliomas in Adults

Wen, Patrick Y.; Kesari, Santosh

doi:10.1056/nejmra0708126

Cited by 3,511

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Malignant Gliomas in Adults

Wen, Patrick Y., Kesari, Santosh·2008·New England Journal of Medicine

DOI 10.1056/nejmra0708126

Open this paper in CoChat — free account

Abstract

Malignant gliomas, the most common type of primary brain tumor in adults, are associated with disproportionate cancer-related morbidity and mortality. Recently, there have been important advances in our understanding of the molecular pathogenesis of malignant gliomas and progress in treating them. This review summarizes the diagnosis and management of these tumors in adults, highlighting new advances.

Integrity signals

Registry

Crossref · 10.1056/nejmra0708126

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glioblastoma is associated with mutations in PTEN and amplification of EGFR.
“Glioblastoma is associated with a number of mutations at the genomic level including mutations in the PTEN tumor suppressor and amplification of the gene encoding the epidermal growth factor receptor (EGFR) [3], [4].”
From Reduced Expression of Brain-Enriched microRNAs in Glioblastomas Permits Targeted Regulation of a Cell Death Gene (2011) · cites this paper as [3]

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372

Flagged first, then by citations

Research works printed but not linked: 104

Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Lyon, France: IARC Press, 2007. · DOI
10.1016/j.ncl.2007.07.004 · DOI
10.1016/j.ncl.2007.07.002 · DOI
10.1136/oem.2006.029751 · DOI
10.1002/ijc.22503 · DOI
10.1056/NEJM200101113440201 · DOI
10.1093/jnci/djm170 · DOI
10.1158/0008-5472.CAN-05-4032 · DOI
10.1016/j.ncl.2007.07.008 · DOI
10.1158/1055-9965.EPI-07-0081 · DOI
10.1007/s00401-007-0243-4 · DOI
Nutt CL, 2003, Cancer Res, 63, 1602
10.1200/JCO.2006.08.0705 · DOI
10.1056/NEJMoa043331 · DOI · Paper page
10.1016/j.ccr.2006.02.019 · DOI
10.1038/ncponc0820 · DOI
10.1101/gad.1596707 · DOI · Paper page
10.1586/14737140.7.11.1581 · DOI
10.1517/14728222.11.4.473 · DOI
10.1002/cncr.22741 · DOI
10.2353/ajpath.2007.070011 · DOI
10.1111/j.1750-3639.1996.tb00848.x · DOI
Ueki K, 1996, Cancer Res, 56, 150
10.1371/journal.pmed.0030485 · DOI
10.1016/j.neuron.2006.07.001 · DOI
10.1038/ng0497-356 · DOI
10.1016/S0002-9440(10)63905-3 · DOI
10.1038/nrn2175 · DOI
10.1016/j.neuron.2007.01.009 · DOI
10.1126/science.1553558 · DOI · Paper page
10.1523/JNEUROSCI.0514-06.2006 · DOI
10.1056/NEJMra043666 · DOI
10.1016/j.neuron.2008.05.031 · DOI
10.1038/nature03128 · DOI
10.1200/JCO.2008.17.6792 · DOI
10.1158/0008-5472.CAN-06-4180 · DOI
10.1038/nrc1889 · DOI
10.1158/0008-5472.CAN-06-1010 · DOI
10.1016/j.ccr.2006.11.020 · DOI
10.1038/nature05236 · DOI
10.1186/1476-4598-5-67 · DOI
10.1002/glia.20414 · DOI
Cha S, 2006, AJNR Am J Neuroradiol, 27, 475
10.1016/j.ncl.2007.07.010 · DOI
10.2967/jnumed.106.037689 · DOI
10.1016/S1470-2045(08)70125-6 · DOI
10.1007/s11060-006-9193-2 · DOI
Glantz MJ, 2000, Neurology, 54, 1886, 10.1212/WNL.54.10.1886 · DOI
10.4065/82.9.1052 · DOI
10.1016/j.ccr.2006.11.021 · DOI · Paper page
10.1200/JCO.2005.04.6656 · DOI
10.1002/ana.410130320 · DOI
Levin JM, 1993, Neurology, 43, 1111, 10.1212/WNL.43.6.1111 · DOI
10.1056/NEJMoa025313 · DOI
Meyers CA, 1998, J Clin Oncol, 16, 2522, 10.1200/JCO.1998.16.7.2522 · DOI
10.1200/JCO.2005.03.3001 · DOI
10.1227/01.NEU.0000103450.94724.A2 · DOI
10.1016/j.ncl.2007.07.006 · DOI
10.1016/S1470-2045(06)70665-9 · DOI · Paper page
10.3171/jns.2001.95.2.0190 · DOI
10.3171/jns.1978.49.3.0333 · DOI
Hochberg FH, 1980, Neurology, 30, 907, 10.1212/WNL.30.9.907 · DOI
10.1097/00006123-200208000-00009 · DOI
10.1016/j.ijrobp.2004.04.011 · DOI
10.1016/j.ijrobp.2005.05.024 · DOI
10.1200/JCO.2007.11.8554 · DOI
10.1200/JCO.2007.11.3985 · DOI
10.1056/NEJMoa065901 · DOI
10.1200/JCO.2004.06.082 · DOI
10.1002/cncr.11323 · DOI
2001, J Clin Oncol, 19, 509, 10.1200/JCO.2001.19.2.509 · DOI
10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S · DOI
10.1016/S0140-6736(02)08091-1 · DOI
10.1215/15228517-5-2-79 · DOI
10.1007/s00701-005-0707-z · DOI
10.1016/j.ncl.2007.07.013 · DOI
10.1158/0008-5472.CAN-06-1796 · DOI
10.1093/jnci/90.19.1473 · DOI
Ino Y, 2001, Clin Cancer Res, 7, 839
10.1093/jnci/djk135 · DOI
10.1200/JCO.2005.04.3414 · DOI
10.1200/JCO.2005.04.6078 · DOI
10.3171/jns.2004.100.1.0041 · DOI
10.1200/JCO.2005.04.7522 · DOI
10.1200/JCO.2005.03.4157 · DOI
Yung WK, 1999, J Clin Oncol, 17, 2762, 10.1200/JCO.1999.17.9.2762 · DOI
Wong ET, 1999, J Clin Oncol, 17, 2572, 10.1200/JCO.1999.17.8.2572 · DOI · Paper page
10.1016/S0140-6736(95)90755-6 · DOI
10.1200/JCO.2004.08.110 · DOI · Paper page
10.1158/1078-0432.CCR-06-0773 · DOI
10.1200/JCO.2005.23.622 · DOI
10.1007/s10637-005-1444-0 · DOI
10.1200/JCO.2006.06.2323 · DOI
10.4161/cc.4.10.2105 · DOI
10.1200/JCO.2003.08.045 · DOI
10.1158/1078-0432.CCR-06-2309 · DOI
10.1200/JCO.2007.12.2440 · DOI
Cloughesy TF, 2008, J Clin Oncol, 26, 91s, 10.1200/jco.2008.26.15_suppl.2010b · DOI
10.1517/14712598.7.2.197 · DOI
10.1200/JCO.2005.03.4082 · DOI
10.1200/JCO.2005.05.4569 · DOI
10.2174/156720107780362302 · DOI
10.1093/jnci/85.9.704 · DOI
Brem SS, 2008, J Natl Compr Canc Netw, 6, 456, 10.6004/jnccn.2008.0037 · DOI

Sorted by citations

IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
Pathomic fusion: an integrated framework for fusing histopathology and genomic features for cancer diagnosis and prognosis
Chen, R. J., Lu, M. Y., Wang, J., Williamson, D. F. K., Rodig, S. J., Lindeman, N. I., & Mahmood, F. (2022) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2020.3021387 · Cited by 729
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma
Shi, Y., Lim, S. K., Liang, Q., Iyer, S. V., Wang, H.-Y., Wang, Z., Xie, X., Sun, D., Chen, Y.-J., Tabar, V., et al. (2019) · Nature · doi:10.1038/s41586-019-0993-x · Cited by 325
SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery
Fan, C.-H., Ting, C.-Y., Lin, H.-J., Wang, C.-H., Liu, H.-L., Yen, T.-C., & Yeh, C.-K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.099 · Cited by 225
Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles
Jia, Y., Wang, X., Hu, D., Wang, P., Liu, Q., Zhang, X., Jiang, J., Liu, X., Sheng, Z., Liu, B., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06556 · Cited by 211
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Self-citation
Itraconazole suppresses the growth of glioblastoma through induction of autophagy: Involvement of abnormal cholesterol trafficking
Liu, R., Li, J., Zhang, T., Zou, L., Chen, Y., Wang, K., Lei, Y., Yuan, K., Li, Y., Lan, J., et al. (2014) · Autophagy · doi:10.4161/auto.28912 · Cited by 178
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma
Yan, F., Alinari, L., Lustberg, M. E., Katherine Martin, L., Cordero-Nieves, H. M., Banasavadi-Siddegowda, Y., Virk, S., Barnholtz-Sloan, J., Bell, E. H., Wojton, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0884 · Cited by 180
Reduced Expression of Brain-Enriched microRNAs in Glioblastomas Permits Targeted Regulation of a Cell Death Gene
Skalsky, R. L., & Cullen, B. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024248 · Cited by 170
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them
Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95
MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes
Liu, F., Gong, J., Huang, W., Wang, Z., Wang, M., Yang, J., Wu, C., Wu, Z., & Han, B. (2014) · Oncogene · doi:10.1038/onc.2013.428 · Cited by 86
Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.
Nunes, A., Al-Jamal, K. T., & Kostarelos, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.026 · Cited by 75
Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype
Jeon, H.-Y., Kim, J.-K., Ham, S. W., Oh, S.-Y., Kim, J., Park, J.-B., Lee, J.-Y., Kim, S.-C., & Kim, H. (2016) · Tumor Biology · doi:10.1007/s13277-015-4439-2 · Cited by 73
In Situ Formation of Nanotheranostics to Overcome the Blood–Brain Barrier and Enhance Treatment of Orthotopic Glioma
Gao, H., Chu, C., Cheng, Y., Zhang, Y., Pang, X., Li, D., Wang, X., Ren, E., Xie, F., Bai, Y., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c03873 · Cited by 59
Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1
Fahey, J. M., Stancill, J. S., Smith, B. C., & Girotti, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000443 · Cited by 59
Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model
Fahey, J. M., Emmer, J. V., Korytowski, W., Hogg, N., & Girotti, A. W. (2016) · Photochemistry and Photobiology · doi:10.1111/php.12636 · Cited by 49
Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery
Fornara, O., Odeberg, J., Wolmer Solberg, N., Tammik, C., Skarman, P., Peredo, I., Stragliotto, G., Rahbar, A., & Söderberg-Nauclér, C. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1036211 · Cited by 45
Upstream signaling events leading to elevated production of pro-survival nitric oxide in photodynamically-challenged glioblastoma cells
Fahey, J. M., Korytowski, W., & Girotti, A. W. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.04.013 · Cited by 38
Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt/β-catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide
Li, H., Liu, S., Jin, R., Xu, H., Li, Y., Chen, Y., & Zhao, G. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00654-2 · Cited by 34
Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
Oh, H., Hwang, I., Jang, J.-Y., Wu, L., Cao, D., Yao, J., Ying, H., Li, J. Y., Yao, Y., Hu, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1810 · Cited by 11
CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas
Murphy, K., & Griffith, T. (2016) · Cancers · doi:10.3390/cancers8080071 · Cited by 11
Exosomal miR-21-5p from glioma associated mesenchymal stem cells promotes the progression and glycolysis of glioblastoma via PDHA1
Zhang, Y., Lv, P., Zhang, Q., Xiang, W., Jiang, X., Guo, Z., & Zhang, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-86580-0 · Cited by 9

Authors: Wen, P. Y., & Kesari, S.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2008-07-31
Volume: 359
Issue: 5
Pages: 492-507
ISSN: 0028-4793
1533-4406
DOI: 10.1056/nejmra0708126
Cited by: 3,511
References: 12
Language: en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Malignant Gliomas in Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks